Vermont's Act 61 sets clear definitions and notice requirements for stem cell practice.
Statute
VT Act 61 (2021), 18 V.S.A. § 4501
Effective
Effective 2021
Vermont's Act 61 provides statutory definitions for stem cell-related products and requires practitioners administering FDA-unapproved therapies to issue a standardized patient notice, obtain signed informed consent, and disclose FDA non-approval status in any related advertisement.
The requirements below are set by VT Act 61 (2021), 18 V.S.A. § 4501. Compliance is the responsibility of each individual treating physician under their state license.
Statutory compliance does not equal FDA approval. The procedures discussed are investigational and have not been approved by the US Food and Drug Administration.
Vermont has enacted VT Act 61 (2021), 18 V.S.A. § 4501, which sets out specific conditions under which a state-licensed physician may practice in this area. The procedures discussed here are investigational and have not been approved by the US Food and Drug Administration.
No. Adults may travel to Vermont from any US state for an in-person consultation with a network physician. Whether any procedure is appropriate is a clinical decision determined by the treating physician.
Cost depends on the indication, the cell product, and the treating physician. Each physician sets their own pricing and provides a written estimate. Select Stem Cell does not collect medical fees on behalf of physicians.
Yes. Vermont law requires the treating physician to provide written disclosure of investigational status and obtain informed consent prior to any procedure.
Continue Reading
We use cookies
We use strictly necessary cookies to make this site work, and (with your permission) functional and analytics cookies to improve your experience. We do not use marketing or behavioral-advertising cookies. Read our Cookie Policy.